Investigators are evaluating the efficacy of a newly developed long-acting monoclonal antibody for preventing severe respiratory syncytial virus (RSV) infections in high-risk premature infants. A total of infants are enrolled and randomized in a 1:1 ratio to receive either the monoclonal antibody or a placebo injection at the start of the RSV season. All participants are followed for days. At the end of the follow-up period, data analysis reveals that infants in the monoclonal antibody group and infants in the placebo group required hospitalization for severe RSV infection.
Based on these study results, what is the number needed to treat to prevent one RSV-related hospitalization?
Answer: 25 patients
Answer
25
The Number Needed to Treat (NNT) quantifies the number of patients who must receive a specific intervention to prevent one additional adverse event. It is calculated by first determining the event rates in both the control and intervention groups. Here, the event rate in the placebo (control) group is . The event rate in the monoclonal antibody (intervention) group is . The Absolute Risk Reduction (ARR) is the difference between these two rates (). Finally, the NNT is the reciprocal of the ARR: . Thus, 25 infants need to receive the monoclonal antibody to prevent one hospitalization for severe RSV.
Step-by-Step Solution
Key Concept
The Number Needed to Treat (NNT) is calculated as the reciprocal of the Absolute Risk Reduction (ARR), where ARR is the difference in event rates between the control and intervention groups ().